For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Attruby represents a significant change. These innovative therapies protect the transthyretin protein, preventing its destructive build-up and lessening the severity of the illness. Individuals are now seeing benefits in their q